The Latest

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference Mont-Saint-Guibert (Belgium), September 13, 2021, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that […]
September 14, 2021

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference

Mont-Saint-Guibert (Belgium), September 13, 2021, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Cantor 2021 Global Healthcare Conference on Tuesday, September 28, 2021, with a virtual presentation at 4:00 pm CET/10:00 am ET.

A live webcast and replay of this event will be available on the Company’s investors relations website at https://investors.nyxoah.com/

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah is seeking for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
vivian.cervantes@gilmartinir.com

Attachment

Previous Article

Gates Foundation’s Annual Goalkeepers Report Finds Stark Disparities in COVID-19 Impacts

Next Article

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Related Posts

Nikkiso Sponsors 2023 Central German Hydrogen Congress and Presents Its Hydrogen Growth Strategy

FREYBURG, Germany, Aug. 30, 2023 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (Group) is pleased to sponsor this year’s Central Hydrogen Congress event and present its hydrogen growth strategy for German and European clean energy markets. Nikkiso’s Clean Energy & Industrial Gases business has more than 50 years of cryogenics experience, and […]

FULC FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action – FULC

NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the “Class Period”), of the important June 27, 2023 lead plaintiff deadline. SO WHAT: If you purchased Fulcrum securities during […]